Molecular labeling of capsules is intended to prevent counterfeiting The Letter of Intent between Applied DNA Sciences, Inc. and ACG grants ACG the rights to use the established SigNature® molecular marking and authentication technologies of Applied DNA.
This allows the development of molecularly labeled empty hard shell capsules to better track and authenticate ACG customers’ products. After the letter of intent, a final agreement is to be concluded.
The empty capsule market has seen healthy growth over the last decade and is expected to increase by 7.2% between 2016 and 2021 and to $ 2.13 billion by 2021.
By developing molecularly labeled empty hard shell capsules, ACG’s customers will be able to enhance the integrity of each distribution channel. It will also provide pharmaceutical companies with more and safer options for investigating suspected counterfeit medicines and helping to strengthen the trust of patients and regulators in pharmaceutical companies and their supply chains.
Using Applied DNA’s SigNature technology, a custom molecular tag can be integrated into one or more capsule component materials. These tags can be designed to stubbornly adhere to a variety of substrates. In addition, they are optimized to verify the authenticity of a product at any point within the pharmaceutical supply chain.
Selbyn Noronha , CEO of ACG Capsules, commented on the merger between ACG and Applied DNA: “More and more counterfeits are being observed in the pharmaceutical supply chain and regulations require companies to adopt strategies such as serialization to address these threats, and there is an urgent need for innovative and effective solutions for product authentication, traceability and integrity of the supply chain.
We firmly believe that our collaboration with Applied DNA is an excellent step to tackle the counterfeiting issue that the industry is currently facing and, with stricter regulatory standards and standards being implemented around the world, existing supply chain safeguards must be in place The merger will give pharmaceutical companies better tools toto prevent counterfeiting through improved tracking solutions across the supply chain.
Dr. James Hayward , President and CEO of Applied DNA, commented: “We are proud to announce the signing of the Memorandum of Understanding and are excited about this new development in ACT, the on-box authentication for hard shell capsules using the SigNature technology Molecular Marking and Authentication The ability to forensically test a capsule and quickly identify its source is a great tool for every node in the pharmaceutical supply chain, making it safer and more traceable. ”
Information about Applied DNA Sciences
Applied DNA is a provider of molecular technologies for supply chain security, counterfeiting and theft, product genotyping, and DNA mass production in diagnostics and therapeutics.
Applied DNA provides innovative, molecular-based technology solutions and services to protect the products, brands, entire supply chains and intellectual property of businesses, governments and consumers from theft, counterfeiting, fraud and theft. The company’s DNA-based CertainT ™ platform can be used to identify, label, validate and track products to ensure the authenticity, origin, traceability, sustainability and quality of the products.
At the center of our security and authenticity solutions is the non-copyable SigNature® DNA platform. It finds a centralized application in a range of products, including SigNature®T and fiberTyping®, textiles and apparel solutions, BackTrac® and DNAnet® to protect against theft and loss, and the powerful digitalDNA® track-and-trace solution. All solutions provide a forensic chain of evidence and can be used in the prosecution of perpetrators. Applied DNA Sciences is also involved in mass production of specific DNA sequences by the polymerase chain reaction.
The ACG Group is the world’s only provider of integrated manufacturing solutions for the pharmaceutical industry. The diverse product offering of capsules, films and coatings, engineering and inspection systems not only meets the requirements of international regulatory requirements, but far surpasses them. ACG has only one goal: to offer everything needed for efficient capsule and tablet production.
ACG has more than 5 decades of experience and is represented in more than 100 countries with more than 4,500 employees around the world. With our customer-oriented approach, maintaining customer relationships, and not least thanks to our sense of value and transparent business practices, we have managed to win many loyal, satisfied customers and partners.